AI Summary (AEO)
- Why does management matter now? Investors are more selective and demand capital efficiency, CMC/Quality maturity and "diligence-ready" governance.
- What is the CAR-T market worth? Estimated at $4.65B (2024), projected to $15.97B by 2030.
- And the cord blood storage market? Estimated at $26.99B (2024) and $41.36B by 2030.
- What is happening with NK in immunotherapy? Market of $340.25M (2024) with accelerated growth; the "off-the-shelf" thesis supports growing attention.
Simone Amaral da Silva Cruz
COO at Axis Biotec Brazil. MBA COPPEAD. Executive with expertise in governance, strategy, finance and operational structuring for health and biotechnology businesses.
A new cycle: less "promise", more execution
Advanced therapies (such as CAR-T and new cellular immunotherapies) are no longer a topic restricted to the scientific frontier and have moved to the center of health innovation strategy. But at the same time, the capital that finances this journey has become more discerning: in 2024, sector analyses pointed to a significant drop in investment volume in cell and gene therapy developers, with investors favoring more "de-risked" paths, clear regulatory routes and, above all, cost control and manufacturing capacity.
This changes the game. Instead of just asking "what does the asset do?", funds and strategic partners now ask, with equal weight:
"How does the company govern risks, control the critical chain (CMC), prove reproducibility and transform science into a scalable product?"
The answer to this is not only in the laboratory. It is in corporate management.
Why governance and corporate management are decisive in advanced therapies
In advanced therapies, risk is "multi-layered": clinical, regulatory, quality, supply chain, pharmacovigilance, data privacy, reimbursement, medical adoption and — in the case of cellular products — industrial execution.
And it is precisely here that good management creates value (and reduces cost of capital):
Diligence has become "readiness audit"
With fewer rounds available, the depth of technical and operational diligence grows: CMC, QA/QC, traceability, cold chain, supplier qualification, scaling capacity and contingency plans.
Capital efficiency is no longer "finance jargon"
Investors want to see clear stage-gates (milestones with objective continuation criteria), portfolio prioritization and data-driven decisions. Fewer unfocused parallel projects, more integration between R&D, quality and regulatory.
"Regulatory-ready operation" is competitive advantage
For cellular products, especially allogeneic and iPSC-derived platforms, literature discusses quality, cost and regulatory framing challenges already in development design.
The size of opportunities: CAR-T, cord blood and NK
The opportunity exists — and it is large. The question is capturing it with execution.
| Segment | Size 2024 | Projection 2030 | CAGR |
|---|---|---|---|
| CAR-T | $4.65B | $15.97B | 22.8% |
| Cord Blood Storage | $26.99B | $41.36B | 7.4% |
| NK Therapeutics | $340.25M | $1.2B | 23.4% |
Sources: Grand View Research (CAR-T and cord blood); Precedence Research (NK). Note: cord estimates may vary by methodology.
NK in immunotherapy: the beginning of a new "industrializable" platform
The NK-based therapies market is still smaller, but attention increases for three theses:
Safety and logistics potential
NK therapies can reduce CAR-T-associated challenges (such as CRS/neurotoxicity) and enable more "ready-to-use" (off-the-shelf) models.
Format innovation
Beyond CAR-NK, bispecific/trispecific engagers (NKCEs) are gaining space.
iPSC and standardization
The iPSC-derived NK agenda emphasizes scalability and standardization, with increasingly mature regulatory discussions.
What funds and partners want to see in 2026: practical management checklist
Below, a checklist that helps transform an advanced therapies company into an "investment-grade" asset:
- Objective governance: clear board/management roles, committees (risk, audit/quality, science)
- Stage-gates with criteria: go/no-go decision based on endpoints, CMC, cost and risk
- Early CMC plan: CQAs, analytical strategy, comparability, stability and materials chain
- Stage-proportional QMS: quality as product — not as "document"
- Manufacturing strategy: CDMO vs internalization, with redundancy and capacity plan
- Living data room: diligence-ready documentation (technical, financial, legal)
- Regulatory risk management: scenarios and evidence for ANVISA/FDA/EMA
- Product economics: COGS, throughput, yield, logistics and access impact
- Access and reimbursement: value evidence generation plan (HEOR/real world)
- People and culture management: lean teams with clear responsibility and metrics
Frequently Asked Questions (FAQ)
Conclusion
Discipline in governance and corporate management is not bureaucracy — it is a direct response to the current environment: less capital available, more focus on execution and clear routes. Companies that adopt this posture become "investment-grade" assets and capture opportunities in a market that, despite challenges, continues to expand.
References
- Grand View Research — CAR-T: 2024 size and 2030 projection.
- Grand View Research — Cord blood banking services: 2024 size and 2030 projection.
- Precedence Research — NK cell therapeutics: 2024 base, projections and CAGR.
- BioPharma Dive (2024) — drop in cell & gene therapy investment.
- FDA — approved/licensed products in cell and gene therapy.
- Review (ScienceDirect, 2025) — engineered NK therapies.
- Springer (2025) — challenges of hiPSC-derived NK.
- White paper JSRM/ISCT iPSC committee.
- Fierce Biotech (2025) — market movements in NK engagers.